ABSTRACT: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 RAs are common therapies for managing diabetes and obesity, but gastrointestinal (GI) adverse effects (AEs) such as nausea, vomiting, diarrhea, and constipation frequently limit therapy
After the US Postal Service intercepted over 100 packages that contained controlled substances, law enforcement searched a warehouse and discovered three pill presses and materials used to make counterfeit pills
The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a median 34.2 months in patients with overweight or obesity and pre-existing cardiovascular disease, independent of glycemic status [12]
The Clinical Case: Why Psychiatrists Are Prescribing GLP-1s The Metabolic-Psychiatric Connection Traditionally, psychiatrists stuck to psychotropics
While the new pricing of GLP-1s would bring down that cost, it would still be relatively higher for GLP-1 users
Free Shipping Your medication is delivered to your door, typically within a week